Biogen (BIIB) And UCB, Inc. (UCBJF.PK) Enter Agreements To Commercialize Multiple Sclerosis And Hemophilia Therapies In Asia
1/30/2014 11:56:57 AM
CAMBRIDGE, Mass. & BRUSSELS, Belgium--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) and UCB (Euronext: UCB) announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China. As part of the relationship, Biogen Idec will supply UCB with its portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA®, FAMPYRA®, AVONEX®, TYSABRI®, PLEGRIDY™ and Daclizumab High-Yield Process (DAC HYP). The relationship also includes ELOCTATE™ and ALPROLIX™, Biogen Idec’s investigational long-acting recombinant candidates for hemophilia A and B, respectively.
Help employers find you! Check out all the jobs and post your resume.
comments powered by